• Debt reduction plan: API Holdings sold a 10% stake in Thyrocare to clear ₹1,050 crore of group-level debt and achieve debt-free status.
• Promoter shareholding floor: API Holdings will retain a 51% stake in Thyrocare post-sale, with management confirming there is no intention to dilute holding below this level.
• Growth and margins: Thyrocare maintained its annual revenue growth guidance of 20% following 26% growth in Q1, prioritizing a 32–33% margin with 20–25% growth over maximizing margin percentages.
• Specialty business expansion: Specialty testing currently accounts for near 0% of revenue, but the company plans to scale this segment to peer levels of 15–20% over the next 3 to 5 years.
• Restructuring and listing: Any capital market moves for API Holdings—including an independent IPO or reverse merger—are at least three to four quarters away and contingent on achieving PBT profitability ex-Thyrocare.